Publications

Huang LW, Sheng Y, Andreadis C, Logan AC, Mannis GN, Smith CC, Gaensler KML, Martin TG, Damon LE, Huang CY, Olin RL. Patterns and Predictors of Functional Decline after Allogeneic Hematopoietic Cell Transplantation in Older Adults. Transplantation and cellular therapy. 2022. PMID: 35247612


Huang LW, Sheng Y, Andreadis C, Logan AC, Mannis GN, Smith CC, Gaensler KML, Martin TG, Damon LE, Huang CY, Olin RL. Patterns and Predictors of Functional Decline after Allogeneic Hematopoietic Cell Transplantation in Older Adults. Transplantation and cellular therapy. 2022. PMID: 35247612


Seshadri M, Crane GM, Gergis U. Ofatumumab for Post-Transplant Lymphoproliferative Disorder. Hematology/oncology and stem cell therapy. 2022. PMID: 32413419


Auclair D, Mansfield C, Fiala MA, Chari A, Cole CE, Kaufman JL, Orloff GJ, Siegel DS, Zonder JA, Mange B, Yesil J, Dalal M, Mikhael JR. Preferences and Priorities for Relapsed Multiple Myeloma Treatments Among Patients and Caregivers in the United States. Patient preference and adherence. 2022. PMID: 35256844


Venook AP. Colorectal Cancer Surveillance With Circulating Tumor DNA Assay. JAMA network open. 2022. PMID: 35258585


Taylor MH, Betts CB, Maloney L, Nadler E, Algazi A, Guarino MJ, Nemunaitis J, Jimeno A, Patel P, Munugalavadla V, Tao L, Adkins D, Goldschmidt JH, Cohen EEW, Coussens LM. Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022. PMID: 34862248


Tempero M. Getting Complex Therapies to More People: A Vexing Dilemma. Journal of the National Comprehensive Cancer Network : JNCCN. 2022. PMID: 35276671


Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Brammer J, Clemens MW, Dogan A, Foss F, Ghione P, Goodman AM, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Jones A, Kallam A, Kim YH, Kumar K, Mehta-Shah N, Olsen EA, Rajguru SA, Rozati S, Said J, Shaver A, Shea L, Shinohara MM, Sokol L, Torres-Cabala C, Wilcox R, Wu P, Zain J, Dwyer M, Sundar H. T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2022. PMID: 35276674


Umashankar S, Mamounas ME, Matthys M, Hadeler EK, Wong EC, Hicks G, Hwang J, Chien AJ, Rugo HS, Hamolsky D, Esserman L, Melisko M. Evaluation of the Pathways for Survivors Program to Address Breast Cancer Survivorship-Associated Distress: Survey Study. JMIR cancer. 2022. PMID: 35212641


Umashankar S, Mamounas ME, Matthys M, Hadeler EK, Wong EC, Hicks G, Hwang J, Chien AJ, Rugo HS, Hamolsky D, Esserman L, Melisko M. Evaluation of the Pathways for Survivors Program to Address Breast Cancer Survivorship-Associated Distress: Survey Study. JMIR cancer. 2022. PMID: 35212641


Umashankar S, Mamounas ME, Matthys M, Hadeler EK, Wong EC, Hicks G, Hwang J, Chien AJ, Rugo HS, Hamolsky D, Esserman L, Melisko M. Evaluation of the Pathways for Survivors Program to Address Breast Cancer Survivorship-Associated Distress: Survey Study. JMIR cancer. 2022. PMID: 35212641


Manzano-Robleda MDC, Espinosa-Tamez P, Potter MB, Hernández-Guerrero A, Van Loon K, Unger-Saldaña K. Capacidad de colonoscopías diagnósticas en la Ciudad de México Salud Publica Mex. 2022. PMID:


Van Loon K, Mohar A, Unger-Saldaña K, Potter MB, Sweet-Cordero EA, Breithaupt L, Espinosa-Tamez P, Sepúlveda-Amor J, Lajous M.. Developing a collaborative international partnership for cancer control in Mexico Salud Publica Mex. 2022. PMID:


Byrnes JR, Weeks AM, Shifrut E, Carnevale J, Kirkemo L, Ashworth A, Marson A, Wells JA. Hypoxia Is a Dominant Remodeler of the Effector T Cell Surface Proteome Relative to Activation and Regulatory T Cell Suppression. Molecular & cellular proteomics : MCP. 2022. PMID: 35217172


Byrnes JR, Weeks AM, Shifrut E, Carnevale J, Kirkemo L, Ashworth A, Marson A, Wells JA. Hypoxia Is a Dominant Remodeler of the Effector T Cell Surface Proteome Relative to Activation and Regulatory T Cell Suppression. Molecular & cellular proteomics : MCP. 2022. PMID: 35217172


Borno HT, Zhang L, Zhang S, Lin TK, Skafel A, Nieves E, Dornsife D, Johnson R, Rhoads K, Small E, Spicer D. Implementation of a Multisite Financial Reimbursement Program in Cancer Clinical Trials Integrated With Patient Navigation: A Pilot Randomized Clinical Trial. JCO oncology practice. 2022. PMID: 35196064


Borno HT, Zhang L, Zhang S, Lin TK, Skafel A, Nieves E, Dornsife D, Johnson R, Rhoads K, Small E, Spicer D. Implementation of a Multisite Financial Reimbursement Program in Cancer Clinical Trials Integrated With Patient Navigation: A Pilot Randomized Clinical Trial. JCO oncology practice. 2022. PMID: 35196064


Borno HT, Zhang L, Zhang S, Lin TK, Skafel A, Nieves E, Dornsife D, Johnson R, Rhoads K, Small E, Spicer D. Implementation of a Multisite Financial Reimbursement Program in Cancer Clinical Trials Integrated With Patient Navigation: A Pilot Randomized Clinical Trial. JCO oncology practice. 2022. PMID: 35196064


Chou J, Trepka K, Sjöström M, Egusa EA, Chu CE, Zhu J, Chan E, Gibb EA, Badura ML, Contreras-Sanz A, Stohr BA, Meng MV, Pruthi RS, Lotan Y, Black PC, Porten SP, Koshkin VS, Friedlander TW, Feng FY. TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells. European urology oncology. 2022. PMID: 35216942